GLP-1RA在2型糖尿病患者心血管中的研究进展

The cardiovascular research progress of GLP-1RA in patients with diabetes mellirus type 2

2型糖尿病(Diabetes mellitus type 2,T2DM)与心血管疾病紧密相关。一些降糖药物会增加体重或低血糖发生率,导致这些药物降糖疗效不能达到预期效果。而胰高血糖素样肽-1受体激动剂(Glucagon-like peptide 1receptor agonists,GLP-1RA)可以降低血糖,在降糖的同时减轻体重,且单独使用不增加低血糖发生风险,临床试验表明GLP-1RA对T2DM患者心血管有保护作用。本文就GLP-1RA T2DM患者的GLP-1RA心血管结局试验及GLP-1RA T2DM患者的心血管事件相关危险因素的影响及心血管获益潜在机制进行综述。

Diabetes mellirus type 2(T2DM)is closely related to cardiovascular disease.Some hypoglycemic drugs can increase the weight or the incidence of hypoglycemia,which may lead to the inability of these drugs to achieve the expected hypoglycemic effect.Glucagon-like peptide-1 receptor agonists(GLP-1RA)can reduce blood glucose and weight loss,and using it alone does not increase the risk of hypoglycemia.Many clinical trials have suggested that GLP-1RA has a cardiovascular protective effect on patients with T2DM.This article reviews the effects of GLP-1RA on cardiovascular outcome testing,cardiovascular event-related risk factors,and potential mechanisms of cardiovascular benefits in patients with T2DM.